In the United States, lung cancer is the leading cause of cancer-related deaths and its impact extends throughout the world. A number of therapies have been approved or are in development to treat specific mutations. However, determining the optimal treatment for each patient is complicated by the difficult process of acquiring tumor samples, along with the time it takes to generate results.
Thermo Fisher’s Oncomine Universal Dx test for NSCLC aims to replace sequential testing with a single, NGS-based assay. The company announced today that it had filed the final module of a premarket approval (PMA) application for the panel, which screens 47 genes and has the potential to add more.
